Abstract: An antigen targeting, anti-CD16A, and immune effector cell activating trifunctional fusion protein has a CD16A binding region that specifically binds to CD16A, a tumor-associated antigen (TAA) binding region that specifically binds to a TAA, an IL-15/IL-15Ra complex formed by combining IL-15 and IL-15Ra, and an Fc domain. A designed tumor-targeting innate immune cell activation molecule, i.e., an anti-TAA, anti-CD 16A, and cytokine IL 15 trifunctional fusion protein targets NK cells to a tumor by simultaneously binding to a TAA on tumor cells and CD16A on NK cells, so that the NK cells release perforin and granzymes to induce apoptosis and cause tumor cell death. The cytokine IL15 expands and maintains the function of the NK cells, stimulates immune cell proliferation, and changes the immune microenvironment of the tumor.

Abstract: Disclosed is an antigen-targeting, anti-CD16A and immune effector cell-activating trifunctional fusion protein, which comprises a CD16A binding region that specifically binds to CD16A, a TAA binding region that specifically binds to a tumor-associated antigen (TAA), an IL-15/IL-15 R? complex formed by means of binding of IL-15 to IL-15 R?, and an FC domain. The designed tumor-targeting innate immune cell activating molecule, i.e. the anti-TAA, anti-CD 16A and cytokine IL15 trifunctional fusion protein, can simultaneously bind to a TAA on a tumor cell and CD16A on an NK cell, thereby making the NK cell target tumors. The NK cell releases perforin and granzyme to induce apoptosis and cause the death of the tumor cells. The cytokine IL 15 is expanded to maintain the function of the NK cell, stimulate the proliferation of immune cells, and change the immune microenviroument of the tumor.

Abstract: Provided are an anti-CD3 antibody variant, a fusion protein, and an application. An anti-CD3 antibody is mutated to obtain a variant thereof. The provided fusion protein comprises: (1) an anti-tumor-associated antigen (TAA)/anti-CD3 bispecific antibody; (2) anti-TAA, anti-CD3 and IL15/IL15Ra-containing multifunctional fusion proteins; and (3) anti-TAA and IL15/IL15Ra-containing fusion proteins. Further provided are a nucleic acid molecule encoding an antibody molecule and a vector, and a pharmaceutical use of the antibody molecule.

Abstract: Provided are a trifunctional fusion protein containing a tumor-associated antigen (TAA) antibody, a TGF-? inhibitor, and a CD3 antibody, and an application thereof. By introducing a TGF-? inhibitor into antibody molecule, the trifunctional fusion protein can specifically target the antibody molecule to tumors by means of a TAA antibody having high affinity; an anti-CD3 antibody can play a T cell killing role; and the TGF-? inhibitor can block a TGF-? signal, thereby promoting the infiltration and activation of T cells in a tumor microenvironment.

Abstract: A bispecific antibody is described. IL15 and IL15R? are respectively introduced into two chains of a first antibody of the bispecific antibody, and the high affinity of IL15 and IL15R? is utilized to form an IL15/IL15R? complex, thereby achieving the correct pairing of a light chain/heavy chain of the first antibody, and solving the problem of incorrectly matching light chains/heavy chains of bispecific antibodies. Meanwhile, the binding activity between the light chain/heavy chain of the first antibody may be further enhanced by adding one or more pairs of disulfide bonds between VH1 and VL1 and between IL15 and IL15R? by mutating the amino acid sequences of variable domains VH1, VL1, IL15 and IL15Ra of the first antibody to obtain correctly paired bispecific multifunctional antibodies targeting cytokines.

Abstract: An anti-SIRP? antibody or an antigen-binding fragment thereof, and use thereof are provided. The anti-human SIRP? monoclonal antibody is obtained by means of immunizing mice, and a chimeric antibody and a humanized antibody are further obtained. The provided anti-SIRP? antibody or antigen-binding fragment thereof can bind to the human SIRP? protein, block the CD47-SIRP? signaling pathway, and have immune regulation effects such as enhancing phagocytosis. Further provided are a pharmaceutical composition and a nucleic acid molecule, and the use of the anti-SIRP? antibody or the antigen-binding fragment thereof in the preparation of a drug for inhibiting or treating diseases.

Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Abstract: A bispecific antibody targeting human claudin and human PDL1 proteins, containing an anti-human claudin18.2 antibody moiety and an anti-PD-L1 antibody moiety. The bispecific antibody can not only bind to human claudin18.2 protein, but also block binding of PD-1/PD-L1, and can not only activate NK cells and kill tumor cells in the innate immunity, but also promote the killing effect of killer T lymphocytes on tumors in the acquired immunity. The bispecific antibody has better anti-tumor efficacy than an anti-claudin18.2 antibody alone.

Abstract: Provided are an anti-PD-L1 nanobody and an Fc fusion protein thereof, and an application thereof. The anti-PD-L1 nanobody and the Fc fusion protein thereof have strong specificity, high affinity, and weak immunogenicity to humans. In addition, same have high stability and a significant anti-tumor effect.

Abstract: Provided are an anti-CLDN18.2 antibody and a pharmaceutical composition thereof and a detection method therefor, wherein the heavy chain of the antibody is selected from any one of SEQ ID NOs: 1-7 or SEQ ID NOs: 15-30, and the light chain of the antibody is selected from any one of SEQ ID NOs: 8-14 or SEQ ID NOs: 31-46. The ability of the antibody to bind to cell lines and tumor tissue cells is more powerful than that of the existing antibody IMAB362, and the anti-tumor effect of the antibody is also more powerful than that of the existing antibody IMAB362.

Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.

Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.

Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and medical uses thereof.

Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.

Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.